Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, April 28, 2015, 56 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $625.00 to $2,071,840.58.

Highlighted Stocks Traded by Insiders:

KCG Holdings (KCG) - FREE Research Report

Daniel V. Tierney 2011 Trust, who is 10% Owner at KCG Holdings, sold 129,158 shares at $13.05 on April 28, 2015. Following this transaction, the 10% Owner owned 8.3 million shares meaning that the stake was reduced by 1.54% with the 129,158-share transaction.

The shares most recently traded at $13.07, up $0.02, or 0.12% since the insider transaction. Historical insider transactions for KCG Holdings go as follows:

  • 4-Week # shares sold: 257,313
  • 12-Week # shares sold: 865,746
  • 24-Week # shares sold: 865,746

The average volume for KCG Holdings has been 283,900 shares per day over the past 30 days. KCG Holdings has a market cap of $1.4 billion and is part of the financial sector and financial services industry. Shares are up 12.36% year-to-date as of the close of trading on Tuesday.

KCG Holdings, Inc., an independent securities firm, provides various services designed to address trading needs across asset classes, product types, and time zones. The company operates through three segments: Market Making, Global Execution Services, and Corporate and Other. The company has a P/E ratio of 24.1. Currently, there are 2 analysts who rate KCG Holdings a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KCG - FREE

TheStreet Quant Ratings rates KCG Holdings as a sell. Among the areas we feel are negative, one of the most important has been poor profit margins. Get the full KCG Holdings Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Capital Bank Financial (CBF) - FREE Research Report

Posner Kenneth A., who is Officer at Capital Bank Financial, bought 3,500 shares at $27.68 on April 28, 2015. Following this transaction, the Officer owned 64,977 shares meaning that the stake was boosted by 5.69% with the 3,500-share transaction.

The shares most recently traded at $27.97, up $0.29, or 1.02% since the insider transaction. Historical insider transactions for Capital Bank Financial go as follows:

  • 4-Week # shares bought: 2,000
  • 12-Week # shares bought: 2,000
  • 24-Week # shares bought: 2,000
  • 24-Week # shares sold: 2,000

The average volume for Capital Bank Financial has been 110,300 shares per day over the past 30 days. Capital Bank Financial has a market cap of $830.7 million and is part of the financial sector and banking industry. Shares are up 2.69% year-to-date as of the close of trading on Tuesday.

Capital Bank Financial Corp. operates as the bank holding company for Capital Bank, National Association that provides various commercial and consumer banking products and services in the southeastern region of the United States. The company has a P/E ratio of 25.7. Currently, there are 4 analysts who rate Capital Bank Financial a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CBF - FREE

TheStreet Quant Ratings rates Capital Bank Financial as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, expanding profit margins, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Capital Bank Financial Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Alimera (ALIM) - FREE Research Report

Bavp, L.P., who is 10% Owner at Alimera, sold 3,114 shares at $5.02 on April 28, 2015. Following this transaction, the 10% Owner owned 4.5 million shares meaning that the stake was reduced by 0.07% with the 3,114-share transaction.

The shares most recently traded at $4.59, down $0.43, or 9.31% since the insider transaction. Historical insider transactions for Alimera go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 72,462
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 74,462
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 80,462

The average volume for Alimera has been 152,600 shares per day over the past 30 days. Alimera has a market cap of $204.0 million and is part of the health care sector and drugs industry. Shares are down 16.97% year-to-date as of the close of trading on Tuesday.

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. The company focuses on diseases affecting the back of the eye or retina. Currently, there are 2 analysts who rate Alimera a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALIM - FREE

TheStreet Quant Ratings rates Alimera as a sell. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself. Get the full Alimera Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null